 1. Histologically or cytologically confirmed low or intermediate grade, unresectable well differentiated foregut neuroendocrine tumors thymic, bronchopulmonary, gastric, duodenal and pancreatic. Patients with multiple neuroendocrine tumors associated with MEN1 syndrome will be eligible. 